Browsing Tag
Durvalumab
6 posts
Why clinicians and regulators are closely watching AstraZeneca’s rare disease and solid tumor pipeline strategy
Why AstraZeneca’s ASCO 2026 rare disease and solid tumor pipeline strategy is drawing major clinical and regulatory attention. Read more.
AstraZeneca’s PACIFIC-2 Phase 3 trial for Imfinzi in NSCLC falls short of primary endpoint
In the latest development in oncology research, AstraZeneca’s PACIFIC-2 Phase III trial, involving Imfinzi (durvalumab) concurrently administered with…
AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study
AstraZeneca’s IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with…
AstraZeneca reports positive results for phase 2 COAST trial of oleclumab and monalizumab
AstraZeneca has reported positive results from the COAST phase 2 trial of its oleclumab or monalizumab in combination…
AstraZeneca’s Imfinzi garners positive opinion from CHMP for NSCLC treatment
AstraZeneca has reached a crucial milestone as the Committee for Medicinal Products for Human Use (CHMP) of the…
FDA removes clinical hold on Advaxis’ Axalimogene Filolisbac, Durvalumab combo trial
Advaxis, a biotech firm based in New Jersey, announced a significant regulatory update as the U.S. Food and…